Etanercept received approval from the US Food and Drug Administration (FDA) in November 1998 as the first anti-tumor necrosis factor agent for the treatment of moderate to severe rheumatoid arthritis (RA) (217). The gene discussed is TNF; the disease is rheumatoid arthritis.